HSV gene transfer in the treatment of chronic pain.
- Author:
David J FINK
1
;
Marina MATA
Author Information
1. University of Michigan and VA Ann Arbor Healthcare System, Ann Arbor, Michigan 48109, USA. djfink@umich.edu
- Publication Type:Journal Article
- MeSH:
Animals;
Chronic Pain;
therapy;
Disease Models, Animal;
Ganglia, Spinal;
cytology;
Gene Transfer Techniques;
Genetic Vectors;
Humans;
Neuralgia;
therapy;
Neurons, Afferent;
cytology;
Simplexvirus
- From:
Acta Physiologica Sinica
2008;60(5):610-616
- CountryChina
- Language:English
-
Abstract:
It has proven difficult to use systemic administration of small molecules to selectively modulate nociception. Over the past decade, we and others have developed non-replicating herpes simplex virus (HSV)-based vectors to treat chronic pain. Subcutaneous inoculation of an HSV vector effectively transduces sensory neurons in the dorsal root ganglion; release of transgene-coded inhibitory neurotransmitters or anti-inflammatory peptides reduces pain-related behaviors in rodent models of chronic inflammatory and neuropathic pain. A phase 1 trial of this therapy in patients is set to begin soon.
